M&A is down, but Big Pharma likely to line up 'multiple shots on goal' in 2nd half, PwC says

Submitted by admin on June 24, 2022 - 10:25am

Source:

Fierce Biotech

News Tags:

M&A

biotech

Pfizer

GSK

PwC

Headline:

M&A is down, but Big Pharma likely to line up 'multiple shots on goal' in 2nd half, PwC says

snippet:

Deal values are down by 58% and volume has decreased by 33%, but fear not, the pharmaceutical and life sciences industry is poised for a “flurry of deals” in the second half, according to PwC.

Search form

You are here

M&A is down, but Big Pharma likely to line up 'multiple shots on goal' in 2nd half, PwC says

M&A is down, but Big Pharma likely to line up 'multiple shots on goal' in 2nd half, PwC says